Latest news
Bioforum The Data Masters announces the opening of a new office and Global Capability Center (GCC) in Bengaluru, India, led by Dr. Santhosh Kumar, who brings over 24 years of industry experience. The center will integrate core capabilities such as clinical data management and statistical programming to support global clinical trial projects, with plans to significantly expand the team over the next year.
Detailed data from Biogen's mid-stage 'Celia' trial show that its tau-targeting drug BIIB080 slowed the decline in CDR-SB scores by 26% in the lowest-dose group over 18 months, comparable to the efficacy of approved amyloid drugs. However, the trial was a technical failure because the dose-response relationship did not meet expectations, yet the company still plans to advance to Phase III. Analysts are divided on the drug's commercial prospects and strategic value.
Allegheny Health Network (AHN) and the START Center for Cancer Research announced a strategic collaboration to establish a new START early-phase clinical trial site within AHN's Allegheny General Hospital, aiming to expand access to early-phase oncology trials for patients in Western Pennsylvania. The collaboration will integrate START's community-based early-phase trial expertise with AHN's network of cancer specialists, enabling patients to participate in trials within their existing care pathways.
A team of scientists successfully developed a customized gene-editing drug for a critically ill infant within months, with preliminary results showing safety and efficacy. This case may provide a replicable pathway for individualized treatment of thousands of ultra-rare diseases, but long-term efficacy and safety still require validation.
ACTO announces its certification as a Veeva Gold Product Partner, continuing nearly a decade of collaboration to deepen AI-driven field excellence and compliant customer engagement.
Novartis and Bristol Myers Squibb have paused multiple trials of their CAR-T therapies in autoimmune disorders following safety incidents, including three deaths in Novartis' case. The news has raised investor questions about the broader autoimmune cell therapy landscape, prompting companies like Kyverna, Cabaletta, and others to emphasize differences in their manufacturing processes and trial designs. Analysts suggest that faster production methods may be linked to the safety issues, while traditional processes and allogeneic approaches could offer safer profiles.
This week, Novartis and Bristol-Myers Squibb paused several clinical trials of CAR-T therapies in autoimmune diseases due to safety incidents such as severe immune reactions, leading to fluctuations in related companies' stock prices and prompting the industry to reassess the risks and prospects in this field.
UniQure has submitted applications to the FDA for its AMT-130 gene therapy, potentially the first approved treatment targeting the underlying cause of Huntington's disease. The company is seeking priority review and accelerated approval based on three-year data showing AMT-130 may significantly slow disease progression. The submission follows a turbulent year that included a drastic change in the FDA's view of the therapy and leadership changes at the agency. Analysts note remaining regulatory risk but are encouraged that UniQure appears aligned with the FDA on a confirmatory study that will not require a sham surgery control. Four-year follow-up data expected by month's end is the next major catalyst.
UniQure announced on Wednesday that it has submitted a marketing application for AMT-130 gene therapy, which could become the first drug to treat the underlying cause of Huntington's disease. The company is seeking FDA priority review and accelerated approval, based on three-year data showing the therapy significantly slows disease progression. Previously, new FDA leadership had questioned its data and required a new double-blind trial, but later shifted stance after leadership changes. Analysts believe regulatory risks remain, but avoiding sham surgery controls makes confirmatory trials more feasible.